Peter Buhl Jensen

3.0k total citations
103 papers, 2.5k citations indexed

About

Peter Buhl Jensen is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Peter Buhl Jensen has authored 103 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Molecular Biology, 64 papers in Oncology and 11 papers in Cancer Research. Recurrent topics in Peter Buhl Jensen's work include Cancer therapeutics and mechanisms (48 papers), Lung Cancer Research Studies (22 papers) and Cancer Treatment and Pharmacology (15 papers). Peter Buhl Jensen is often cited by papers focused on Cancer therapeutics and mechanisms (48 papers), Lung Cancer Research Studies (22 papers) and Cancer Treatment and Pharmacology (15 papers). Peter Buhl Jensen collaborates with scholars based in Denmark, United States and Singapore. Peter Buhl Jensen's co-authors include Maxwell Sehested, Annemette Thougaard, Seppo W. Langer, Lars H. Jensen, Ellen Friche, Erland J.F. Demant, Boe Sandahl Sørensen, Ib Jarle Christensen, Bente Holm and Fredrik Björkling and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Peter Buhl Jensen

101 papers receiving 2.4k citations

Peers

Peter Buhl Jensen
Elisabetta Leo United Kingdom
Erkan Baloglu United States
Daniel Glaubiger United States
Dona Alberti United States
Katherine A. Kennedy United States
François Lokiec France
Fernando Vidal‐Vanaclocha Spain
Jan M. Woynarowski United States
Wynne Aherne United Kingdom
Jacques Jolivet Canada
Elisabetta Leo United Kingdom
Peter Buhl Jensen
Citations per year, relative to Peter Buhl Jensen Peter Buhl Jensen (= 1×) peers Elisabetta Leo

Countries citing papers authored by Peter Buhl Jensen

Since Specialization
Citations

This map shows the geographic impact of Peter Buhl Jensen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Buhl Jensen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Buhl Jensen more than expected).

Fields of papers citing papers by Peter Buhl Jensen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Buhl Jensen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Buhl Jensen. The network helps show where Peter Buhl Jensen may publish in the future.

Co-authorship network of co-authors of Peter Buhl Jensen

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Buhl Jensen. A scholar is included among the top collaborators of Peter Buhl Jensen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Buhl Jensen. Peter Buhl Jensen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nielsen, Dorte, Erik Jakobsen, Sven Tyge Langkjer, et al.. (2023). Predictive biomarker for cisplatin in prospective phase 2 of liposomal cisplatin in metastatic breast cancer.. Journal of Clinical Oncology. 41(16_suppl). 3130–3130.
2.
Christensen, Ib Jarle, Eva Balslev, Ann Knoop, et al.. (2019). Prediction of fulvestrant efficacy in patients with advanced breast cancer: retrospective-prospective evaluation of the predictive potential of a multigene expression assay. Breast Cancer. 27(2). 266–276. 1 indexed citations
3.
Glimelius, Bengt, Nebojša Manojlović, Per Pfeiffer, et al.. (2017). Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx ® ): a placebo-controlled randomised phase II study (PLIANT). Acta Oncologica. 57(3). 393–402. 63 indexed citations
4.
Vangsted, Annette Juul, Jack B. Cowland, Peter Buhl Jensen, et al.. (2017). Drug response prediction in high-risk multiple myeloma. Gene. 644. 80–86. 12 indexed citations
5.
Langer, Seppo W., Annemette Thougaard, Maxwell Sehested, & Peter Buhl Jensen. (2011). Treatment of experimental extravasation of amrubicin, liposomal doxorubicin, and mitoxantrone with dexrazoxane. Cancer Chemotherapy and Pharmacology. 69(2). 573–576. 12 indexed citations
6.
Beck, Hans Christian, et al.. (2010). Proteomic profiling of human colon cancer cells treated with the histone deacetylase inhibitor belinostat. Electrophoresis. 31(16). 2714–2721. 15 indexed citations
7.
Jensen, Mette Munk, Kamille Dumong Erichsen, Fredrik Björkling, et al.. (2010). Early Detection of Response to Experimental Chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in Human Ovary Cancer Xenografts in Mice. PLoS ONE. 5(9). e12965–e12965. 32 indexed citations
8.
Poulsen, Christian Bjørn, Lise Mette Rahbek Gjerdrum, Peter de Nully Brown, et al.. (2009). Histone deacetylase 1, 2, 6 and acetylated histone H4 in B‐ and T‐cell lymphomas. Histopathology. 54(6). 688–698. 102 indexed citations
9.
Gjerdrum, Lise Mette Rahbek, et al.. (2008). Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T‐cell lymphoma. Histopathology. 53(3). 267–277. 97 indexed citations
10.
Grauslund, Morten, et al.. (2005). Separation of bisdioxopiperazine- and vanadate resistance in topoisomerase II. Biochemical and Biophysical Research Communications. 334(3). 853–860. 2 indexed citations
11.
12.
Walker, Jerrylaine V., Karin C. Nitiss, Lars H. Jensen, et al.. (2004). A Mutation in Human Topoisomerase II α Whose Expression Is Lethal in DNA Repair-deficient Yeast Cells. Journal of Biological Chemistry. 279(25). 25947–25954. 16 indexed citations
13.
Schroeder, Patricia, Kenneth Francis Hofland, Peter Buhl Jensen, et al.. (2003). Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent. Cancer Chemotherapy and Pharmacology. 53(1). 91–93. 6 indexed citations
14.
Jensen, Peter Buhl, et al.. (2000). A dose escalating study of topotecan preceding cisplatin in previously untreated patients with small-cell lung cancer. Annals of Oncology. 11(7). 829–835. 27 indexed citations
15.
16.
Falck, Jacob, Peter Buhl Jensen, & Maxwell Sehested. (1999). Evidence for Repressional Role of an Inverted CCAAT Box in Cell Cycle-dependent Transcription of the Human DNA Topoisomerase IIα Gene. Journal of Biological Chemistry. 274(26). 18753–18758. 27 indexed citations
17.
Sehested, Maxwell, Peter Buhl Jensen, Boe Sandahl Sørensen, et al.. (1993). Antagonistic effect of the cardioprotector (+)-1,2-BIS(3,5-dioxopiperazinyl-1-YL)propane(ICRF-187) on dna breaks and cytotoxicity induced by the topoisomerase ii directed drugs daunorubicin and etoposide (VP-16). Biochemical Pharmacology. 46(3). 389–393. 81 indexed citations
18.
Demant, Erland J.F., Peter Buhl Jensen, & Maxwell Sehested. (1991). Characterization of the cooperative cross-linking of doxorubicin N-hydroxysuccinimide ester derivatives to water soluble proteins. Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology. 1118(1). 83–90. 6 indexed citations
19.
Friche, Ellen, Peter Buhl Jensen, Henrik Roed, Torben Skovsgaard, & N. I. Nissen. (1990). In vitro circumvention of anthracycline-resistance in ehrlich ascites tumour by anthracycline analogues. Biochemical Pharmacology. 39(11). 1721–1726. 24 indexed citations
20.
Demant, Erland J.F., Maxwell Sehested, & Peter Buhl Jensen. (1990). A model for computer simulation of P-glycoprotein and transmembrane ΔpH-mediated anthracycline transport in multidrug-resistant tumor cells. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1055(2). 117–125. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elisabetta Leo Breakdown of academic impact, for papers by Erkan Baloglu Breakdown of academic impact, for papers by Daniel Glaubiger Breakdown of academic impact, for papers by Dona Alberti Breakdown of academic impact, for papers by Katherine A. Kennedy Breakdown of academic impact, for papers by François Lokiec Breakdown of academic impact, for papers by Fernando Vidal‐Vanaclocha Breakdown of academic impact, for papers by Jan M. Woynarowski Breakdown of academic impact, for papers by Wynne Aherne Breakdown of academic impact, for papers by Jacques Jolivet
Rankless by CCL
2026